Announce topline results from the ALTITUDE-AD Phase 2 study
Deadline not yet reached (65 days left)
- Announced
- 16 Sep 2026
- Due
- 31 Dec 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Phase 2 topline results expected late 2026”
What we found
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift -31 days
- 2 versions
-
Version 1 · original · stated 16 Sep 2026
Deadline 31 Dec 2026 (“late 2026”) · wording expected
-
Version 2 · stated 26 Oct 2026
Deadline 30 Nov 2026 (“in November 2026”) · wording expected
“we expect to report topline results in November 2026”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Announce
- Language
- Expected (“expects”, “plans”)
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Acumen Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2026-ABOS-000759 · Corrections policy